上海医药公告，2025年上半年营业收入1415.93亿元，同比增长1.56%。净利润44.59亿元，同比增长 51.56%。 ...

Group 1 - The stock price of Honghui Fruits and Vegetables is reported at 9.33 yuan, down 0.16 yuan from the previous trading day, with a decline of 1.69% [1] - The opening price for the day was 9.47 yuan, reaching a high of 9.54 yuan and a low of 9.24 yuan, with a trading volume of 270,017 hands and a transaction amount of 253 million yuan [1] - Honghui Fruits and Vegetables is primarily engaged in the planting, purchasing, processing, and sales of fruit and vegetable products, operating within the agriculture, animal husbandry, and fishery industry [1] Group 2 - Recently, the company established a wholly-owned subsidiary, Shanghai Juhui Ze Pharmaceutical Technology Co., Ltd., with a registered capital of 10 million yuan, focusing on goods and technology import and export [1] - On August 25, the net outflow of main funds for Honghui Fruits and Vegetables was 27.86 million yuan, accounting for 0.52% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 38.51 million yuan, representing 0.72% of the circulating market value [1]

Group 1 - The Shanghai Composite Index rose by 1.51% to close at 3883.56 points, while the Hang Seng Index increased by 1.94% to 25829.91 points [1] - Shanghai Pharmaceuticals Holding Co., Ltd. (referred to as "the company") has an AH premium of 66.35%, ranking 50th in AH stock premium rates [1] - The company's A-shares closed at 19.48 yuan, with a rise of 1.94%, and its H-shares closed at 12.79 Hong Kong dollars, increasing by 1.59% [1] Group 2 - The company is a large pharmaceutical group listed in both Shanghai and Hong Kong, with stock codes 02607 on the Hong Kong Stock Exchange and 601607 on the Shanghai Stock Exchange [1] - The company's main business covers pharmaceutical manufacturing and commerce, and it is included in the SSE 180 Index, CSI 300 Index, and MSCI China Index [1] - The company advocates core values of "innovation, integrity, cooperation, inclusiveness, and responsibility," aiming to enhance the quality of public health and become a respected leading brand in pharmaceutical manufacturing and health services [1] - The company is committed to innovation and has been increasing its investment in research and development to accelerate its transformation and development [1]

Group 1: Core Announcement - Shanghai Pharmaceuticals has received drug registration certificates for Oxytocin Injection and Acetate Octreotide Injection from the Philippines Food and Drug Administration, allowing these products to be marketed in the Philippines [1][5] Group 2: Product Information - Oxytocin Injection is primarily used for induction and stimulation of labor, as well as for treating uterine bleeding due to insufficient contraction [2] - Acetate Octreotide Injection is used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, and preventing complications after pancreatic surgery [2][3] - Both products were developed by Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical Pharmaceutical Co., Ltd., with minimal additional registration costs of approximately RMB 50,000 for the Philippines market [2][3] Group 3: Market Competition - In the Philippines, there are 12 other vendors for Oxytocin Injection, including RAQUEL ABBAS PHARM and AMB HK ENTERPRISE, while Acetate Octreotide Injection faces competition from NOVARTIS PHARMA and SUN PHARMA among others [4] - The total sales for Oxytocin Injection in the Philippines market is projected to be USD 970,000 in 2024, while Acetate Octreotide Injection is expected to generate USD 760,000 [4] Group 4: Impact on Company - The approval of these injections marks a significant step for Shanghai Pharmaceuticals in expanding its overseas market presence and gaining valuable experience [5]

Core Insights - Shanghai Pharmaceuticals announced the approval of its products, Oxytocin Injection and Acetate Octreotide Injection, by the Philippines Food and Drug Administration [2] Company Summary - The company’s subsidiary, Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd., received drug registration certificates for the aforementioned products [2] - The approved drugs are now set to be marketed in the Philippines [2]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyuan Biochemical Pharmaceutical Co., Ltd., has received drug registration certificates from the Philippines Food and Drug Administration for its Oxytocin Injection and Acetate Octreotide Injection, allowing these products to be marketed [1] Group 1: Product Details - Oxytocin Injection is primarily used for induction of labor, postpartum hemorrhage due to uterine atony, and assessing placental reserve function [1] - Acetate Octreotide Injection is used for treating acromegaly, alleviating symptoms related to functional gastrointestinal endocrine tumors, preventing complications after pancreatic surgery, and managing esophageal variceal bleeding [1] Group 2: Development Background - Oxytocin Injection was developed by PAR STERILE PRODUCTS and was first launched in the United States in 1980 [1] - Acetate Octreotide Injection was developed by NOVARTIS and was first launched in the United States in 1988 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received drug registration certificates for oxytocin injection and octreotide acetate injection from the Philippines Food and Drug Administration, allowing the company to sell these products in the Philippine market, which positively impacts its overseas market expansion and accumulates valuable experience [1]. Group 1 - Shanghai Pharmaceuticals' subsidiary, Shanghai First Biochemical Pharmaceutical Co., Ltd., produced the approved drugs, indicating the company's capability in pharmaceutical manufacturing [1]. - The approved oxytocin injection (1mL:10 units) and octreotide acetate injection (1mL:0.1mg) signify the company's compliance with international regulatory standards [1]. - The registration marks a significant step for the company in expanding its presence in the Southeast Asian pharmaceutical market [1].

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於縮宮素注射液及醋酸奧曲肽注射液獲得菲律賓藥品 註冊證書的公告》、《上海醫藥集團股份有限公司關於召開 2025 年半年度業績說明會的公告》 僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 8 月 23 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士 ...

证券代码：601607 证券简称：上海医药 编号：临2025-077 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海上药第一生化药业有限公司（以下简称"上药第一生化"）生产的缩宫素 注射液及醋酸奥曲肽注射液收到菲律宾食品药品监督管理局颁发的药品注册证 书，前述药品获得批准上市。 上海医药集团股份有限公司 关于缩宫素注射液及醋酸奥曲肽注射液 获得菲律宾药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1 一、药品基本情况 药品名称：缩宫素注射液 药品名称：醋酸奥曲肽注射液 剂型：注射剂 注册证号：DRP-16801 二、药品相关的信息 缩宫素注射液主要用于引产、催产、以及产后、流产后因宫缩无力或缩复不 良而引起的子宫出血；了解胎盘储备功能（催产素激惹试验）。由 PAR STERILE PRODUCTS 研发，最早于 1980 年在美国上市。1994 年 10 月，上药第一生化的 缩宫素注射液在国内获批上市。截至本公告日，公司针对该药品在菲律宾的上市 未投入额外的研发费用，仅注册 ...

重要内容提示： 投资者可于 2025 年 08 月 22 日（星期五）至 08 月 28 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 上海医药集团股份有限公司（以下简称"公司"）将于 2025 年 8 月 28 日盘 后发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 08 月 29 日（星期五）15:0 0-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 证券代码：601607 证券简称：上海医药 公告编号：临 2025-078 上海医药集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、参加人员 本次投资者说明会以音频形式召开，公司将针对 2025 年半年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就 ...